Memantine for prevention of migraine: A retrospective study of 60 cases

Andrew Charles, Charles Flippen, Marcela Romero Reyes, Kevin C. Brennan

Research output: Contribution to journalReview articlepeer-review


The objective was to retrospectively characterise the efficacy of memantine as preventive therapy in a series of patients with frequent migraine. Patients in a university headache clinic completed a survey regarding their experience with memantine, and medical records were reviewed. All patients who received memantine as preventive therapy for migraine over a 15-month period were mailed surveys and consent forms for record review. Patients were treated with memantine beginning at a dose of 5 mg/day, increasing if needed by 5 mg/week up to 10 mg twice a day. The majority of patients (36 out of 54) treated with memantine for at least 2 months reported a significant reduction in estimated headache frequency, and improved function. Side effects were uncommon and generally mild. This limited retrospective case review suggests that memantine may be an effective preventive therapy for patients with frequent migraine. A prospective trial is warranted.

Original languageEnglish (US)
Pages (from-to)248-250
Number of pages3
JournalJournal of Headache and Pain
Issue number4
StatePublished - Sep 2007


  • Glutamate
  • Headache
  • Memantine
  • Migraine
  • Prevention

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Memantine for prevention of migraine: A retrospective study of 60 cases'. Together they form a unique fingerprint.

Cite this